fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Primidone

All products: general benefit

Primidone · DIN 00396761 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Primidone · DIN 00396761 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2011-07-21 · brand PRIMIDONE · ATC N03AA03 PRIMIDONE · form Tablet · route Oral · ingredients PRIMIDONE 250 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Primidone: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0887). What the ministry pays, not the patient.

Ministry pays: $0.0887 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00396761)

Source record
DIN 00396761: Primidone Raw flags: sec3=Y Item: 281200024; group id 443; item number 1110; lccId None; manufacturer id AAP Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0887; ministry $0.0887 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00396761 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2750
Interchangeable products
Mysoline · DIN 02042355 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00396761
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N03A, N03AA): coverage varies; not interchangeable

  • Phenobarbital (Phenobarbital Injection): limited Use 481
  • Carbamazepine (Tegretol): general benefit, limited Use, not a benefit, listing status unconfirmed
  • Clonazepam (Rivotril): general benefit
  • Divalproex (Epival): general benefit
  • Ethosuximide (Zarontin): general benefit
  • Lamotrigine (Lamictal): general benefit

14 more in the class list below

Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, LAMOTRIGINE, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

PHENOBARBITAL

· 1 products · Limited Use, codes 481 · strengths: 120mg/mL · Inj Sol-1mL Pk

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit (25), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications PRIMIDONE (primidone tablets) is indicated for use alone or in combination with other anticonvulsants for the control of grand mal and psychomotor seizure in patients 8 years of age and older. 1.1. Pediatric Pediatrics (< 8 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of PRIMIDONE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. Pediatrics (8 to 18 years of age): See 4.2. Recommended Dose and Dosage Adjustment and 7.1.3. Pediatrics. 1.2. Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.1. Dosing Considerations and 7.1.4. Geriatrics. https://pdf.hres.ca/dpd_pm/00082233.PDF PM date: not printed or not captured Source product: PRIMIDONE; DIN 00396761; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.